top of page
Drug Science

Psilocybin for Anorexia Nervosa


In this webinar, Dr Meg Spriggs explains the potential of psilocybin to treat anorexia nervosa, and offers valuable insights from the clinical trial investigating this application at the Centre for Psychedelic Research.


Eating disorders are a complex mental health issue with few effective pharmaceutical treatments available.


Meg provides an introductory background to some of the therapeutic mechanisms of psilocybin and the design of the psilocybin for anorexia nervosa clinical trial.


Dr. Meg Spriggs completed her PhD in psychology at the University of Auckland, New Zealand. Following her passions for neuroscience and mental health, she joined the team at the Centre for Psychedelic Research at Imperial College London in 2018 where she works as a co-ordinator and guide on studies of psilocybin in healthy volunteers and patient populations. She is one of the lead researchers on the centre’s trial looking at psilocybin in the treatment of anorexia nervosa; a devastating disorder with no currently approved treatments.


This webinar was part of the Student Psychedelic Conference, 2021. To receive updates about the next Student Psychedelic Conference, join the Drug Science Mailing list.

Drug Science is the leading independent scientific body on drugs in the UK. We rely on donations to provide clear, evidence-based information without political or commercial interference. Drug Science webinars are free, and always will be, so if you’d like to support us then please consider joining the Drug Science Community.

Keep up with developments in drug science

Reading, engaging with, and sharing our publications, papers and commentary gives evidence-based science and policy the audience it needs and deserves.

bottom of page